Showing 1641-1650 of 7669 results for "".
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen, director of AboutSkin Dermatology and DermSurgery in Englewood and Lone Tree, Colorado and As…
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal …
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She was recognized at the ADAM annual meeting in Denver. Ms…
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new line will launch o…
- Sciton Announces Launch of Halo at AAD Annual Meetinghttps://practicaldermatology.com/news/20140320-sciton_announces_launch_of_halo_at_aad_annual_meeting/2459309/Sciton announced the launch of Halo, a hybrid fractional laser that applies tunable non-ablative and ablative wavelengths in a single pass to maximize results and reduce downtime. Sciton will be premiering Halo at the 72nd Annual Meeting of the American Academy of Dermatology.…
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. Hemangeol is an oral solution specially devel…
- Pollogen to Launch FDA-Cleared Imogen at AAD Annual Meetinghttps://practicaldermatology.com/news/20140318-pollogen_to_launch_fda-cleared_imogen_at_aad_annual_meeting/2459312/Pollogen Ltd., will launch its Imogen system in the United States during the upcoming American Academy of Dermatology (AAD) meeting in Denver. The Imogen System is FDA cleared for dermatological procedures requiring ablation and resurfacing of the skin using the VoluDerm appli…
- Doctors Issue New Treatment Guidelines for Skin Abscesses Caused By MRSAhttps://practicaldermatology.com/news/20140317-doctors_issue_new_treatment_guidelines_for_skin_abscesses_caused_by_mrsa/2459315/It has been more than 10 years since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and doctors are still grappling with how to diagnose, treat and prevent this virulent form of staph infection, which is immune to many antibiotics, according to…
- Phase I Trial of Nivolumab Shows Long-Term Efficacy Against Melanomahttps://practicaldermatology.com/news/20140313-phase_i_trial_of_nivolumab_shows_long-term_efficacy_against_melanoma/2459318/A recent study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions, published online in the Journal of Clinical Oncology, provides the longest-term look so far at how melanoma patients have fared since receiving the drug, nivolumab (Bri…
- Deepak Chadha is New Vice President of Regulatory Affairs for Suneva Medicalhttps://practicaldermatology.com/news/20140311-deepak_chadha_is_new_vicepresident_of_regulatory_affairs_for_suneva_medical/2459319/Suneva Medical appointed Deepak Chadha to Vice President of Regulatory Affairs. Chadha's role will be leading the development and implantation of regulatory practices. Chairman and Chief Executive Officer, Nicholas L. Teti, Jr. said, “Deepak has been responsible for several global regulatory stra…